Literature DB >> 15944054

Oral fluid testing for driving under the influence of drugs: history, recent progress and remaining challenges.

Alain G Verstraete1.   

Abstract

In recent years the demand for drug testing in oral fluid in cases of driving under the influence has been increasing. The main advantages of saliva/oral fluid are the possibility for non-medical personnel to collect it without embarrassment and a better correlation between presence of drugs in oral fluid and impairment. Several surveys have been performed since the 1980s using saliva, and researchers encountered problems related to insufficient sample volume and insufficient sensitivity of the analytical methods. Steady progress has been shown in sample collection, knowledge of toxicokinetics in oral fluid, reliability of on-site and laboratory-based immunoassays and confirmation methods. In a few countries, legislation was passed that allows the use of saliva as a matrix for screening or confirmation. Despite this progress, some more work needs to be done, principally in the areas of the sensitivity and reliability of on-site screening devices, particularly for cannabis and benzodiazepines, knowledge about passive contamination and more generalised proficiency testing before oral fluid testing for DUID will have the reliability needed to be used forensically.

Entities:  

Mesh:

Year:  2005        PMID: 15944054     DOI: 10.1016/j.forsciint.2004.11.023

Source DB:  PubMed          Journal:  Forensic Sci Int        ISSN: 0379-0738            Impact factor:   2.395


  19 in total

1.  Disposition of cannabinoids in oral fluid after controlled around-the-clock oral THC administration.

Authors:  Garry Milman; Allan J Barnes; David M Schwope; Eugene W Schwilke; William D Darwin; Robert S Goodwin; Deanna L Kelly; David A Gorelick; Marilyn A Huestis
Journal:  Clin Chem       Date:  2010-06-08       Impact factor: 8.327

2.  Cannabinoids and metabolites in expectorated oral fluid following controlled smoked cannabis.

Authors:  Garry Milman; David M Schwope; David A Gorelick; Marilyn A Huestis
Journal:  Clin Chim Acta       Date:  2012-01-20       Impact factor: 3.786

3.  S(+)amphetamine induces a persistent leak in the human dopamine transporter: molecular stent hypothesis.

Authors:  Aldo A Rodriguez-Menchaca; Ernesto Solis; Krasnodara Cameron; Louis J De Felice
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

4.  Drinking, drugs and driving in Ireland: more evidence for action.

Authors:  P Fitzpatrick; L Daly; C P Leavy; D A Cusack
Journal:  Inj Prev       Date:  2006-12       Impact factor: 2.399

5.  Oral fluid cannabinoid concentrations following controlled smoked cannabis in chronic frequent and occasional smokers.

Authors:  Sebastien Anizan; Garry Milman; Nathalie Desrosiers; Allan J Barnes; David A Gorelick; Marilyn A Huestis
Journal:  Anal Bioanal Chem       Date:  2013-08-17       Impact factor: 4.142

6.  Performance evaluation of the DrugWipe® 5/5+ on-site oral fluid screening device.

Authors:  Anna Pehrsson; Tom Blencowe; Kari Vimpari; Antti Impinen; Teemu Gunnar; Pirjo Lillsunde
Journal:  Int J Legal Med       Date:  2010-07-23       Impact factor: 2.686

7.  Oral fluid cocaine and benzoylecgonine concentrations following controlled intravenous cocaine administration.

Authors:  Kayla N Ellefsen; Marta Concheiro; Sandrine Pirard; David A Gorelick; Marilyn A Huestis
Journal:  Forensic Sci Int       Date:  2016-01-22       Impact factor: 2.395

8.  Drug testing in oral fluid.

Authors:  Olaf H Drummer
Journal:  Clin Biochem Rev       Date:  2006-08

9.  Simultaneous quantification of cannabinoids and metabolites in oral fluid by two-dimensional gas chromatography mass spectrometry.

Authors:  Garry Milman; Allan J Barnes; Ross H Lowe; Marilyn A Huestis
Journal:  J Chromatogr A       Date:  2010-01-04       Impact factor: 4.759

10.  Oral fluid cannabinoids in chronic cannabis smokers during oral δ9-tetrahydrocannabinol therapy and smoked cannabis challenge.

Authors:  Dayong Lee; Ryan Vandrey; Damodara R Mendu; Sebastien Anizan; Garry Milman; Jeannie A Murray; Allan J Barnes; Marilyn A Huestis
Journal:  Clin Chem       Date:  2013-08-12       Impact factor: 8.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.